Quick Listen: Scrip’s Five Must-Know Things

02 Dec 2024

In this week's episode: Marks on Trump’s threat to FDA; Amgen’s Phase II MariTide data lack clarity; Roche’s Poseida buyout; Roche’s CMO on his biotech lessons; and what Trump 2.0 might mean for India.

Scrip Five Must Know Things — weekly audio roundup of selected content from Scrip's global team

Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip‘s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 29 November 2024, including: Marks on Trump’s threat to FDA; Amgen’s Phase II MariTide data lack clarity; Roche’s Poseida buyout; Roche’s CMO on his biotech lessons; and what Trump 2.0 might mean for India.

This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

Marks Believes Trump Team Won’t Threaten US FDA’s Medicines Expertise

Amgen’s Phase II MariTide Data Lack Clarity Market Hoped For

Roche Softens TIGIT Blow With Poseida Buyout

Novartis Benefits From Biotech Lessons Taught By Development Head Aradhye

Trump 2.0: India Pharma On A Good Wicket?

Citeline · Scrip's Five Must-Know Things - 2 December 2024

Quick Listen: Scrip’s Five Must-Know Things

07 Jul 2025

• By Ian Haydock

In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.

Quick Listen: Scrip’s Five Must-Know Things

30 Jun 2025

• By Ian Haydock

In this week's episode: top drugs in the first quarter; deal trends at bio; Novo and Lilly’s obesity segmentation plans; Chinese firms at ADA; and five drugs that surpassed sales expectations.

Post-BIO Podcast: Thoughts From The Frontlines

26 Jun 2025

• By Sarah Karlin-Smith, Mandy Jackson, and Mary Jo Laffler

Scrip and Pink Sheet journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.

Quick Listen: Scrip’s Five Must-Know Things

23 Jun 2025

• By Ian Haydock

In this week's episode: US policies in spotlight at BIO; Lilly’s Verve acquisition; UroGen’s bladder cancer approval; Ireland’s biopharma talent; and Korea proposes new AI R&D project.

Venture Funding Plummets In Q2 As Mega-Rounds Falter

08 Jul 2025

• By Mandy Jackson

Evaluate’s second quarter data show that VC rounds of $100m or more totaled $2.36bn, down from $5.25bn in Q2 of 2024. Overall, the Q2 total dropped year-over-year to $4.92bn from $7.95bn.

Stock Watch: US CAR-T And Vaccine Actions: Net Negative For Access

08 Jul 2025

• By Andy Smith

Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.